Noninvasive fetal RHD testing is emerging as a standard of care: insights from a global survey
Alloimmunization against Rhesus D (RhD) is the leading cause of hemolytic disease of the fetus and...
In this case study, Dr. Papasavva describes her laboratory’s journey from traditional thalassemia testing to state-of-the-art NGS technology and what a difference this has made in their daily work.
Whitepaper
This whitepaper provides an evidence-based overview of HbF genetic modifiers, their biological mechanisms, their clinical relevance, and how they should currently be interpreted in practice.
Alloimmunization against Rhesus D (RhD) is the leading cause of hemolytic disease of the fetus and...
Read More
The supply of anti-D immunoglobulin, a prophylactic cornerstone of maternal care, has come under...
Read More
Over the past decade, there has been a wealth of research investigating the ideal approach to RHD...
Read More
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
Read More